BENRALIZUMAB (Fasenra) prior authorization at Aetna
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Aetna requires Interleukin-5 Receptor alpha-directed Cytolytic Antibody prior-authorization documentation for BENRALIZUMAB (Fasenra): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return in 30 days; if denied, prescribers and members have 180 days to appeal.
The PA criteria you'll need to meet
Aetna reviews BENRALIZUMAB (Fasenra) prior authorizations against its medical policy for Interleukin-5 Receptor alpha-directed Cytolytic Antibody. Aetna-specific context: Owned by CVS Health since 2018. CVS Caremark is the PBM. Aetna ASA administers self-funded ERISA plans. Meritain Health is Aetna's TPA brand.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in Interleukin-5 Receptor alpha-directed Cytolytic Antibody
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Aetna's medical policy URL referenced in the cover letter
Aetna's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- UM-2575 medical necessity denials
- Prior auth absent
- Step therapy on specialty drugs
- Out-of-network ER reduction
BENRALIZUMAB (Fasenra)-specific denial patterns and context
Across payers (not just Aetna), BENRALIZUMAB (Fasenra)draws a distinct set of denial reasons rooted in the drug's label, REMS, and competitive landscape:
- Eosinophil count threshold (≥300 cells/µL within 12 months)
- Step therapy requiring mepolizumab first within IL-5 class
- Indication restriction (severe asthma vs EGPA — December 2024)
Brand: Fasenra. IL-5 receptor α monoclonal antibody. Approved for severe eosinophilic asthma; expanded to eosinophilic granulomatosis with polyangiitis (EGPA) September 2024.
Manufacturer patient-assistance program: Benra360 Patient Support — relevant when an Aetna denial sticks and the patient needs bridge access while appealing.
How Aetna approaches Biologic drugs (mAbs and biosimilars) PAs
Aetna's Biologic drugs (mAbs and biosimilars) reviewer typically anchors BENRALIZUMAB (FASENRA) prior-auth decisions on step therapy on specialty drugs. Pharmacy-benefit review for BENRALIZUMAB (FASENRA) at Aetna is routed through CVS Caremark (parent CVS Health since 2018). The 30-day standard review window starts when the prior-authorization request is received with all required documentation — incomplete packets pause the clock and add 5-10 days to time-to-approval, after which the 180-day internal-appeal window begins from the denial date. Aetna's utilization-management vendor (Carelon, eviCore, OptumRx, or in-house) sets the step-therapy ladder — appeals that cite ACR, AAD, or AGA guideline language directly to the medical director shorten escalation. Aetna is domiciled in CT, so unresolved appeals escalate to the CT insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead). Owned by CVS Health since 2018.
If the PA is denied
Aetna gives prescribers and members 180 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://www.aetnaprovider.com) with the same packet plus a peer-reviewed citation supporting BENRALIZUMAB (Fasenra)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal an Aetna denial on DenialHelp.
Contact Aetna
- Provider portal: https://www.aetnaprovider.com
Frequently asked questions
What documentation does Aetna need for BENRALIZUMAB (Fasenra) prior auth?
Aetna's typical PA packet for BENRALIZUMAB (Fasenra): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For Interleukin-5 Receptor alpha-directed Cytolytic Antibody, expect clinical-criteria documentation specific to this class.
What's the turnaround time at Aetna?
Standard BENRALIZUMAB (Fasenra) PA decisions at Aetna: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136.
What does Aetna most often reject BENRALIZUMAB (Fasenra) for?
Across Aetna's book the common rejection patterns include: UM-2575 medical necessity denials; Prior auth absent; Step therapy on specialty drugs. For BENRALIZUMAB (Fasenra) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
What prior failures does Aetna typically require before approving BENRALIZUMAB (FASENRA)?
Aetna's biologics step-therapy ladder for most indications begins with a conventional DMARD (methotrexate, sulfasalazine, leflunomide) or topical/inhaled first-line, then a step-1 biologic (typically a TNF inhibitor or adalimumab biosimilar), then the requested agent. Document trial duration (≥12 weeks for most biologics), dosing reached, and reason for discontinuation (inadequate response by disease-activity score, intolerance, or contraindication). For BENRALIZUMAB (FASENRA), attach the specific disease-activity instrument Aetna accepts (e.g., DAS28, PASI 75, HBI, Mayo) — appeals with raw symptom narrative but no scored instrument carry higher denial rates. Pharmacy-benefit handling is routed through CVS Caremark (parent CVS Health since 2018). External-review escalation for Aetna fully-insured policies sits with the CT insurance department.
How do I prep for a peer-to-peer with Aetna on BENRALIZUMAB (Fasenra)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the BENRALIZUMAB (Fasenra) PA packet
Open ApprovalHelp — generate a BENRALIZUMAB (Fasenra) prior-auth packet tailored to Aetna's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com